Helius Medical Technologies (OTCMKTS:HSDT) Raised to Hold at Zacks Investment Research – Riverton Roll

Posted: Published on January 20th, 2020

This post was added by Alex Diaz-Granados

Zacks Investment Research upgraded shares of Helius Medical Technologies (OTCMKTS:HSDT) from a sell rating to a hold rating in a research note published on Wednesday morning, Zacks.com reports.

According to Zacks, Helius Medical Technologies Inc. is a specialty medical device company. It is focused on the development and regulatory approval of its non-invasive neurostimulation device called PoNS. The Company is nearing clinical trials for balance disorders in TBI patients and for the treatment of MS. Helius Medical Technologies, Inc. is based in Newtown, Pennsylvania.

Shares of HSDT stock opened at $1.12 on Wednesday. Helius Medical Technologies has a 1-year low of $0.28 and a 1-year high of $8.42. The firms 50-day simple moving average is $0.74 and its 200-day simple moving average is $1.48.

Helius Medical Technologies (OTCMKTS:HSDT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.22) earnings per share for the quarter, hitting the Thomson Reuters consensus estimate of ($0.22). The company had revenue of $0.15 million for the quarter, compared to analysts expectations of $0.30 million.

Hedge funds have recently made changes to their positions in the company. Morgan Stanley lifted its holdings in shares of Helius Medical Technologies by 302.7% during the 2nd quarter. Morgan Stanley now owns 14,072 shares of the companys stock worth $31,000 after acquiring an additional 10,578 shares during the period. A.R.T. Advisors LLC acquired a new stake in Helius Medical Technologies during the 2nd quarter worth approximately $35,000. Bank of Montreal Can increased its position in Helius Medical Technologies by 6,777.4% during the 2nd quarter. Bank of Montreal Can now owns 20,701 shares of the companys stock worth $45,000 after purchasing an additional 20,400 shares in the last quarter. Paloma Partners Management Co acquired a new stake in Helius Medical Technologies during the 2nd quarter worth approximately $177,000. Finally, Millennium Management LLC increased its position in Helius Medical Technologies by 627.9% during the 3rd quarter. Millennium Management LLC now owns 207,895 shares of the companys stock worth $343,000 after purchasing an additional 179,336 shares in the last quarter.

About Helius Medical Technologies

Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brains ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.

Read More: Resistance Level

Get a free copy of the Zacks research report on Helius Medical Technologies (HSDT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

View original post here:
Helius Medical Technologies (OTCMKTS:HSDT) Raised to Hold at Zacks Investment Research - Riverton Roll

Related Posts
This entry was posted in Medical Technology. Bookmark the permalink.

Comments are closed.